Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04633278
Title CMP-001 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Checkmate Pharmaceuticals
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.